Sturgeon growth-hormone suppressor (Somatostatin AsSS1)

What this is

Somatostatin AsSS1 is a 28-amino-acid peptide derived from the Chinese sturgeon (Acipenser sinensis), one of the most ancient bony fish lineages still alive today. It is the processed form of a somatostatin precursor — a hormone best known for its role in suppressing growth hormone release — and is one of two somatostatin variants encoded in the sturgeon genome (Li and colleagues 2009). Researchers use it as a tool peptide to study the growth hormone secretagogue receptor (GHSR), the Class A GPCR through which ghrelin and synthetic secretagogues such as GHRP-2, hexarelin, and the FDA-approved diagnostic agent macimorelin act. The stored sequence SANGNPAMAPRERKAGCKNFFWKTFTSC contains two cysteine residues (positions 17 and 28) that, like the ring-closing disulfide in the classical somatostatin-14 core, are expected to form a disulfide bond in the folded peptide — a structural feature not visible in the raw single-letter sequence.

History

Somatostatin itself was first isolated from ovine hypothalamus in the early 1970s as a factor that inhibited growth hormone secretion from rat pituitary cells. Decades later, researchers recognised that fish carry at least two distinct somatostatin genes — SS1 and SS2 — arising from an ancient whole-genome duplication event, and that these paralogs diverged in both sequence and tissue expression. Li and colleagues (2009) cloned and characterised both somatostatin genes from the Chinese sturgeon (Acipenser sinensis), a critically endangered anadromous species belonging to order Acipenseriformes — a lineage whose earliest fossils trace back to the Cretaceous period. Their work showed that AsSS1 encodes a 116-amino-acid preprosomatostatin with a 24-amino-acid signal peptide, and that the functional peptide produced corresponds to a 28-residue processed form retaining the canonical SS-14 sequence at its C-terminus. Chinese sturgeon, with their cartilaginous skeletons and ancient body plan, occupy a key position in vertebrate phylogeny, making their neuropeptide repertoire informative for understanding how the somatostatin–GH axis evolved across jawed vertebrates.

What it does

Somatostatin peptides act primarily to suppress growth hormone secretion from the pituitary gland, an effect well documented across teleost and non-teleost fish (Li and colleagues 2009). AsSS1 and its sister gene product AsSS2 are both expressed in the brain and pituitary of Chinese sturgeon, though they differ in peripheral distribution: AsSS2 is more widely expressed in peripheral tissues, and in the hypothalamus of one-to-five-year-old sturgeon, AsSS2 — but not AsSS1 — maintained stable expression over that developmental window (Li and colleagues 2009). Because somatostatin family members, including the closely related neuropeptide cortistatin, have been shown to act at GHSR — the receptor through which the "hunger hormone" ghrelin drives GH release and appetite — AsSS1 is catalogued as a GHSR-targeting research peptide. The GHSR itself is a constitutively active GPCR that signals primarily through the Gαq/11 → phospholipase C → IP3 → intracellular calcium cascade, and its activation by ghrelin or synthetic secretagogues such as hexarelin or GHRP-2 drives a broad programme including GH secretion, increased food intake, modulation of glucose and lipid metabolism, and protective effects in cardiac and neuronal tissues (Yin and colleagues 2014).

Evidence

• Human: No human clinical trials of AsSS1 have been registered. Macimorelin, an unrelated synthetic GHSR agonist, received FDA approval in 2017 as an oral diagnostic test for adult GH deficiency and represents the clinical benchmark for this receptor target.
• Animal: Expression of both AsSS1 and AsSS2 was characterised in brain, pituitary, and peripheral tissues of Chinese sturgeon across developmental stages (Li and colleagues 2009). Broader somatostatin biology in fish — including GH-suppressive effects — is supported by extensive literature across teleost and chondrostean species.
• In vitro: Hexarelin and GHRP-2 bind and activate GHSR1a in pituitary cell and cell-line models, and modulate GH, ACTH, cortisol, and prolactin secretion (Korbonits and colleagues 1995; Molica and colleagues 2010). Specific GHSR binding data for AsSS1 itself has not been reported in the current literature.

Known effects

• Growth hormone suppression — Mechanistic only; inferred from somatostatin family class membership and brain/pituitary expression in Chinese sturgeon (Li and colleagues 2009)
• GHSR modulation — Mechanistic only; no cell-based or in vivo GH secretagogue receptor assay data published for this specific peptide
• Pituitary–hypothalamic axis expression — Documented; AsSS1 mRNA detected in brain and pituitary of A. sinensis (Li and colleagues 2009)

Regulatory status

• US: Not a regulated pharmaceutical; no IND or NDA on record. AsSS1 is used exclusively as a research reagent.
• EU: No regulatory classification.
• WADA: Not listed. (As a non-approved investigational peptide, it falls under S0 — non-approved substances — in the WADA Prohibited List framework.)

Mechanism

GHSR1a is a Class A GPCR with unusually high constitutive activity relative to most GPCRs. Agonist-evoked signalling proceeds through Gαq/11, which activates phospholipase C to produce IP3 and diacylglycerol; IP3 triggers calcium release from the endoplasmic reticulum, and the resulting cytoplasmic calcium transient is the primary signal for GH secretion in pituitary somatotrophs (Yin and colleagues 2014). Downstream, GHSR also couples to AMPK (mediating cardio- and neuroprotective effects), PI3K/AKT (modulating insulin signalling and glucose metabolism), mTOR (mediating orexigenic effects in the hypothalamus), and MAPK/ERK1/2 (promoting cell proliferation and differentiation) (Yin and colleagues 2014). Somatostatin peptides in vertebrates act through their own five-member receptor family (SSTR1–SSTR5), all Gαi/o-coupled GPCRs that inhibit adenylyl cyclase. The somatostatin and ghrelin receptor systems are functionally intertwined: somatostatin suppresses ghrelin secretion, and the GHSR1a and SSTR5 receptors are known to interact, with receptor co-expression altering downstream G-protein coupling. The somatostatin family member cortistatin — more closely related to AsSS1 than to mammalian SS-14 in some structural respects — has been reported to engage GHSR directly in addition to its own SSTR binding. Whether AsSS1 similarly engages GHSR as a direct ligand, rather than through indirect pathway cross-talk, has not been established in published binding studies.

Related peptides

• Somatostatin (SS-14) — the conserved 14-residue mammalian neuropeptide whose ring-closing disulfide forms the binding pharmacophore shared by AsSS1
• Ghrelin — the endogenous GHSR agonist and "hunger hormone" whose receptor AsSS1 is assigned to as a target
• GHRP-2 (pralmorelin) — a synthetic hexapeptide GHSR agonist used in GH stimulation research (Korbonits and colleagues 1995; Molica and colleagues 2010)